News

EANM Focus Meeting 3

Topic: Molecular Imaging and Theranostics in Neuroendocrine Tumours

The third edition of the EANM Focus Meeting comprises 5 tracks, aiming for a consensus statement, based on the tangible results of the multidisciplinary discussions.

Track 1 Imaging of NET
Track 2 Imaging and Therapy of Pheochromocytoma and Paraganglioma
Track 3 PRRT of NET
Track 4 Treatment Monitoring
Track 5 Look into the Future

 

The aim of the meeting is to provide an in-depth overview and critical assessment of the latest development and future directions in the management of neuroendocrine tumours, with a focus on the role of neuroimaging in general and nuclear medicine in particular. The goal is to arrive at a multidisciplinary consensus on the current state of the art and to make expert recommendations on how to advance the field towards establishing clinical impact.

 

Registration Fees

Early Registration Fee (until October 25, 2019) EUR 650.00
Late Registration Fee (from October 26, 2019) EUR 850.00

You are cordially invited to attend the third EANM Focus Meeting in the Wyndham Grand Hotel in Athens, Greece, on January 30–February 1, 2020. Registrations are limited to 250 participants and will be allocated on a first-come, first-served basis, so please reserve your attendance as soon as possible.

 

CME Points

The EANM Focus 3: The International Conference on “Molecular Imaging and Thearanostics in Neuroendocrine Tumours”, Athens, Greece, 30/01/2020-01/02/2020 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 15 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

 

Meeting Venue

Hotel Wyndham Grand Athens
2 Megalou Alexandrou
104 37, Athens
GREECE

 

For any further information have a look at the Focus Meeting website.

We hope to welcome you to the beautiful city of Athens in early 2020 for the third edition of this exciting new EANM initiative.

This website uses cookies. Learn more